Management of Healed Coronary Lesions with Low Residual Stenosis

Rationale for Medical Management

The American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions recommend medical management for lesions with insignificant disease (less than 50% coronary stenosis) 1
A 20% residual stenosis is well below the 50% threshold that would typically warrant consideration for revascularization, according to the American College of Cardiology 1, 2
For intermediate stenoses (40-70%), functional assessment with FFR or iFR is recommended to determine hemodynamic significance before intervention, as stated by the European Society of Cardiology 3
The presence of a healed vulnerable plaque without significant stenosis does not change the recommendation for medical management, as the primary determinant for intervention is the degree of stenosis and its hemodynamic impact, according to the European Society of Cardiology 3

Visual assessment of coronary stenosis correlates poorly with hemodynamic significance, as reported by the European Society of Cardiology 3
Only stenoses >90% reliably predict hemodynamic relevance (96% correct classification), according to the European Society of Cardiology 3
For stenoses between 40-70%, functional assessment is recommended, with only 31% of 40-49% stenoses and 35% of 50-70% stenoses being hemodynamically significant, as stated by the European Society of Cardiology 3
A 20% stenosis would be extremely unlikely to cause ischemia or hemodynamic compromise, according to the European Society of Cardiology 3

Stenting a non-significant lesion (20% stenosis) carries procedural risks without clear benefit, including procedural complications, need for dual antiplatelet therapy, risk of in-stent restenosis, and potential for stent thrombosis, as reported by the American College of Cardiology 1, 2, 4, 5

Optimal medical therapy should include antiplatelet therapy (aspirin), statin therapy to stabilize plaque, and risk factor modification (hypertension, diabetes, smoking cessation), as recommended by the European Society of Cardiology 4, 6
ACE inhibitors/ARBs should be used for ventricular dysfunction, according to the European Society of Cardiology 6

Revascularization would be indicated if stenosis progresses to >50% with evidence of ischemia, or if the patient develops refractory symptoms despite optimal medical therapy, as stated by the American College of Cardiology and the European Society of Cardiology 1, 6
Functional testing demonstrating significant ischemia in the territory or lesion characteristics suggesting instability would also warrant consideration for revascularization, according to the American College of Cardiology and the European Society of Cardiology 4, 6